GlassScriptPhysician profile
Juan F Mella
NPI 1629185897
$3,405.76
in general payments reported to CMS, 2019-2025
28 companies · $818 in 2025
The $818 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $106 · 2021: $525 · 2022: $532 · 2023: $333 · 2024: $414 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,485.70 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $425.74 | 2019-2025 | Tezspire, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $384.68 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $377.11 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Regeneron Healthcare Solutions, INC. | $296.56 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $215.13 | 2021-2025 | Glassia |
| Genzyme Corporation | $200.33 | 2024-2025 | |
| Grifols USA, LLC | $199.90 | 2019-2025 | Prolastin-C Liquid |
| Allergan, INC. | $175.74 | 2019 | |
| Pfizer INC. | $150.21 | 2019-2022 | |
| Philips North America LLC | $131.46 | 2019-2025 | Vest Therapy Und |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.02 | 2019-2023 | Ofev |
| Sanofi-Aventis U.S. LLC | $114.88 | 2019-2025 | |
| Electromed, INC. | $90.82 | 2022-2025 | Smartvest |
| Otsuka America Pharmaceutical, INC. | $81.33 | 2021-2025 | Rexulti, Abilify Maintena |
| Verona Pharma, INC. | $68.99 | 2025 | Ohtuvayre |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $46.23 | 2020-2022 | |
| Advanced Respiratory, INC | $38.15 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $37.37 | 2019-2021 | |
| Tepha INC | $35.40 | 2019 | |
| Mylan Specialty L.P. | $32.69 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $29.90 | 2023 | Opsumit |
| Amgen INC. | $29.86 | 2019-2022 | |
| Resmed Corp | $29.01 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.79 | 2025 | Caplyta |
| Insmed, INC. | $22.74 | 2025 | Arikayce |
| Abbott Laboratories | $18.23 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.46 | 2019 | |
| Shire North American Group INC | $14.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Mella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.